Aerovate Therapeutics Inc

NASDAQ:AVTEUnited States

Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The Company's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The Company has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. It anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101. It has conducted Phase III trial.

Contact Information

Headquarters

200 Berkeley Street, Floor 18BOSTON, MA, United States 02116

Phone

617-443-2400

Fax

302-655-5049

Executives

Independent Chairman of the Board

Mark Iwicki

President, Chief Operating Officer, Secretary

Benjamin Dake

Chief Executive Officer, Director

Timothy Noyes

Chief Financial Officer, Treasurer

George Eldridge

Senior Vice President - CMC

Marinus Verjiws